11.16.01m, Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty
Independence Blue Cross removed the 75% nasal obstruction threshold requirement for septoplasty and rhinoplasty/septorhinoplasty, eliminating an objective measurement barrier. The policy now requires a 4-week medication trial and documented symptoms for vestibular stenosis treatment, adds cleft lip/palate and congenital craniofacial deformities as covered indications, removes multiple ICD-10 codes from coverage criteria, and classifies absorbable nasal implants (e.g., Latera) as experimental/investigational (not covered). These changes take effect March 30, 2026.